Andrew Sinclair

Andrew has more than 10 years experience as an analyst in the pharmaceutical and biotechnology sectors. At Abingworth, he evaluates opportunities in public companies and is a fund manager for open market transactions.

He joined Abingworth in 2008 from HSBC Global Markets, where he was Senior Equity Analyst, Director, responsible for investment research in the mid-cap pharmaceutical sector. Previously, Andrew held biotechnology analyst positions at Credit Suisse and SG Cowen. He completed a PhD in Chemistry and Genetic Engineering at the BBSRC Institute of Plant Science, Norwich, and holds a BSc in Microbiology from King’s College London. Andrew qualified as a chartered accountant with KPMG.